MonoGen, Inc.
TSX : MOG

MonoGen, Inc.

March 10, 2008 09:00 ET

MonoGen Announces Addition of John P. Witkowski as Vice President of Operations

CHICAGO, ILLINOIS--(Marketwire - March 10, 2008) - MonoGen, Inc. ("Corporation") (TSX:MOG) today announced the addition of John P. Witkowski to its senior management team in the capacity of Vice President of Operations. Mr. Witkowski comes to MonoGen from Accellent, Inc., a fully integrated outsource manufacturing and engineering service provider to the medical device industry with particular focus in the cardiology, endoscopy and orthopedic markets, where he was Director of Operations for two manufacturing sites. Prior to that, Mr. Witkowski was with Stryker Orthopaedics, where he also served as Director of Operations. Mr. Witkowski earned his BS in Industrial Engineering from the Georgia Institute of Technology and his MBA from Iona College in New York.

Mr. Witkowski commented "I am thrilled to join such an exciting company and to work with this committed management team. I am confident that my background will serve me well to help drive MonoGen's success going forward."

Ted S. Geiselman, MonoGen's President and CEO commented, "The addition of John to our senior team solidifies our preparedness from a management perspective for the road ahead. His education, experience and enthusiasm are a perfect fit for MonoGen. We couldn't be more excited about his arrival here."

About MonoGen

With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical diagnostics company developing fully automated devices for anatomic pathology laboratories. MonoGen's initial product, the MonoPrep Processor, has been designed to automate processes performed by these laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.

Forward-Looking Statements

To the extent any statements made in this press release contain information that is not historical, these statements are essentially forward-looking in nature and are subject to risks and uncertainties. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements.

Forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to MonoGen USA and us. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause our actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to, our ability to raise additional capital, our ability to execute our business plan while maintaining at all times our various regulatory approvals, and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and we undertake no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information